지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
이 논문의 연구 히스토리 (2)
- 이 논문의 후속연구가 궁금하신가요?
- 연관 학술논문 또는 학술발표를 통해 보다 발전된 연구결과를 확인하실 수 있습니다.
- 이 논문의 연구 히스토리 확인하기
초록· 키워드
오류제보하기
Objectives: This was to evaluate the current usage of three erythropoietin stimulating agents (ESA) and their efficacy for management of anemia in peritoneal dialysis (PD) patients with chronic kidney disease. Methods: It was a retrospective comparative study through review of electronic medical records of chronic kidney disease patients undergoing PD at a tertiary teaching hospital from January 1998 to June 2013. Results: Average administration frequency was 1.66 times/week in EPO group, 0.75 times/week in DA group, and 0.19 times/week in MPG-EPO group. At the first 4 weeks, there were significant differences in mean hemoglobin levels between EPO and DA groups (9.25±1.28 g/dL, 10.02±0.95 g/dL each, p = 0.018) and also in hemoglobin response rates (10.0%, 45.2% each, p = 0.008), but since after 4 week, there had been no significant differences. There also showed no significant differences in achievement of hemoglobin target between the two groups. When converted to MPG-EPO in EPO/DA groups, there showed a slight increase in hemoglobin levels of both groups. MPG-EPO was the highest compared with two other drugs by the average cost based on the average weekly dose. Conclusion: EPO, DA, and MPG-EPO showed similar effects in treatment of anemia of PD patients based on hemoglobin target range (11.0~12.0 g/dL) which NFK-K/DOQI guidelines suggest. Though the average cost of MPG-EPO was higher than the other two drugs, the number of PD patients using MPGEPO has increased and it is thought that long half-life and low administration frequency of MPG-EPO have improved the compliance of PD patients who have to self-administrate.
목차
등록된 정보가 없습니다.
참고문헌 (23)
참고문헌 신청
/ 2006 / KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease / Am J Kidney Dis 47 (5 suppl 3) : S11 ~ S145
Ahn SC. / 1994 / Anemia in patients with chronic renal failure on hemodialysis / Kidney Res Clin Pract 13 (4) : 769 ~ 775
Chul Woo Yang / 2013 / Current status and future in patients with end stage renal disease in KOREA / 대한의사협회지 56 (7) : 560 ~ 561
Curran MP. / 2008 / Methoxy polyethylene glycolepoetin beta : A review of its use in the management of anaemia associated with chronic kidney disease / Drugs 68 (8) : 1139 ~
Dougherty FC. / 2004 / Continuous erythropoiesis receptor activator (CERA) provides dosedependent erythropoietic activity with a prolonged half-life in healthy volunteers /
Ahn SC. / 1994 / Anemia in patients with chronic renal failure on hemodialysis / Kidney Res Clin Pract 13 (4) : 769 ~ 775
Chul Woo Yang / 2013 / Current status and future in patients with end stage renal disease in KOREA / 대한의사협회지 56 (7) : 560 ~ 561
Curran MP. / 2008 / Methoxy polyethylene glycolepoetin beta : A review of its use in the management of anaemia associated with chronic kidney disease / Drugs 68 (8) : 1139 ~
Dougherty FC. / 2004 / Continuous erythropoiesis receptor activator (CERA) provides dosedependent erythropoietic activity with a prolonged half-life in healthy volunteers /
이 논문의 저자 정보
최근 본 자료
댓글(0)
0